IMMUNOMEDICS INC
IMMUNOMEDICS INC (IMMU): 3 pipeline candidates · ~97 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
97.1 months
D/E 0.82 · 0% dilution
Lead: Phase 3
3 candidates
N/A
N/A
A transparent, data-derived signal for IMMUNOMEDICS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$974.6M
Quarterly Burn
$30.8M
Runway
97.1 mo
Revenue
$20.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| immu-130 | Preclinical |
| immu-140 | Preclinical |
| sacituzumab govitecan | Phase 3 |
Frequently asked questions
How many drug candidates are in IMMUNOMEDICS INC's pipeline?
IMMUNOMEDICS INC (IMMU) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is IMMUNOMEDICS INC's lead drug candidate?
IMMUNOMEDICS INC's most advanced tracked candidate is immu-130 (Preclinical) for Cancer.
What is IMMUNOMEDICS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, IMMUNOMEDICS INC has approximately 97.1 months of cash runway.
Who is the CEO of IMMUNOMEDICS INC?
Alder Bio is the chief executive officer of IMMUNOMEDICS INC (IMMU).
Get the full picture on IMMUNOMEDICS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.